Celsense is Issued Patent for MRI Cell Tracking Product
Pittsburgh, PA (PRWEB) December 22, 2011 Celsense, Inc., announced today that it has received a Notice of Allowance for US Patent Application 10/586,015 with claims covering its MRI cell tracking product, Cell Sense.
Cell Sense is a perfluorocarbon tracer agent used to label cells ex vivo, making them detectable in vivo after transplantation using magnetic resonance imaging (?MRI?). Invented by Eric Ahrens at Carnegie Mellon University, Cell Sense can be used to non-invasively image the administration, migration, and persistence of cells transplanted for therapeutic or diagnostic purposes using MRI. The use of Cell Sense was first reported in the journal Nature Biotechnology in 2005.
Cell Sense is currently available for use in preclinical research and human clinical trials. The first clinical use of Cell Sense is in combination with an autologous dendritic cell vaccine used to treat colorectal cancer; the trial was authorized by the US FDA in May of 2011. It is contemplated